Sun Pharmaceutical Industries Share Price Analysis April 2026
Sun Pharmaceutical Industries Ltd.
1. Business Overview
Sun Pharmaceutical Industries Ltd., founded in 1983 by Dilip Shanghvi, is India’s largest listed pharmaceutical company and ranks among the top 10 global generics players. Headquartered in Mumbai, it operates manufacturing facilities across India, the US, Europe, and other markets, with a presence in over 150 countries and exports to approximately 90 nations.
The company’s business spans three primary verticals: branded formulations (cardiology, CNS, gastroenterology, ophthalmology, dermatology), specialty generics (injectables, inhalants, complex products), and Active Pharmaceutical Ingredients (APIs). The US and India are the two largest revenue contributors, with the US alone contributing roughly 30–35% of revenues. Sun commands an 8.4% domestic market share — the highest in India.
The company is pivoting from pure generics toward high-margin specialty and innovative medicines. Key innovative assets include Ilumya® (tildrakizumab, plaque psoriasis), Cequa® (cyclosporine ophthalmic), and a clinical pipeline of five novel entities. Recent acquisitions — Concert Pharmaceuticals (2023, alopecia), Taro (2024, US dermatology generics), and Polaris Biotech (2025, oncology) — have meaningfully expanded its specialty capabilities.
2. Historical Financial Performance
| Metric | FY21 | FY22 | FY23 | FY24 | FY25E | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 28,572 | 32,963 | 40,068 | 48,497 | 52,578 | 15,469* |
| Revenue Growth | — | 15.4% | 21.6% | 21.0% | 8.4% | 15.1% YoY |
| EBITDA (₹ Cr) | 6,850 | 8,200 | 10,400 | 13,700 | 16,200 | 4,780* |
| EBITDA Margin | 24.0% | 24.9% | 26.0% | 28.3% | 30.8% | 30.9% |
| Net Profit (₹ Cr) | 5,150 | 6,530 | 7,820 | 10,929 | 12,800 | 3,369* |
| PAT Margin | 18.0% | 19.8% | 19.5% | 22.5% | 24.3% | 21.8% |
| EPS (₹) | 21.5 | 27.2 | 32.6 | 45.5 | 53.3 | 14.70* |
| 5-Year Revenue CAGR | ~16% (13-yr historical) | ~10% (projected) | ||||
*Quarterly figure. FY25E = estimated full-year. Historical figures are approximate based on published annual data.
Sun Pharma has delivered consistent double-digit earnings growth over the last four quarters, with net profit rising from ₹2,141 Cr to ₹3,369 Cr — an average quarterly expansion of 13.3%. Revenue has grown at a 5-year CAGR of approximately 10% (FY21–FY25), while operating margins have expanded structurally from ~24% to ~31%, reflecting the shift toward specialty products which carry 40–50% gross margins versus ~25–30% for generics.
3. DCF Valuation
Discounted Cash Flow Analysis — 10-Year FCF Model
| Year | Revenue (₹ Cr) | FCF Margin | FCF (₹ Cr) | PV @ 12% |
|---|---|---|---|---|
| FY26E | 59,200 | 18% | 10,656 | 9,514 |
| FY27E | 66,000 | 19% | 12,540 | 10,004 |
| FY28E | 74,000 | 20% | 14,800 | 10,541 |
| FY29E | 82,000 | 20% | 16,400 | 10,420 |
| FY30E | 91,000 | 21% | 19,110 | 10,843 |
| FY31–FY35E | Tapering growth 8–11% | ~1,10,000 | ~55,000 | |
| Terminal Value (PV) | ~3,20,000 Cr | ~1,62,000 Cr | ||
4. Buy Range — Entry Zones
5. Buy Scenario Analysis
6. Sell Range — Exit Zones
7. Sell Scenario Analysis
8. Future Growth & Earnings Potential
Sun Pharma is well-positioned to compound earnings at 12–15% over the next three years, driven by multiple growth levers. The company’s India business — now commanding 8.4% market share — continues to benefit from volume-led growth and new product launches (26 in FY26 so far). In Q3 FY26, the India formulations segment grew 16% YoY, while Emerging Markets and RoW grew 28% and 21% respectively.
The most significant near-term catalyst is the GLP-1 semaglutide launch. Sun has received approvals for both weight management (Noveltreat) and Type 2 diabetes (Sematrinity) indications in India at competitive weekly pricing of ₹900–₹2,000. With patent expiries in India, Canada, and Brazil potentially unlocking over ₹50 billion in industry revenue, Sun is well-placed to capture a meaningful share of this high-growth market alongside Dr. Reddy’s and Alkem.
The global specialty business — anchored by Ilumya® (tildrakizumab) for plaque psoriasis and Cequa® — is expected to continue growing 20%+ annually. Five novel entities are in clinical stage, representing longer-dated but high-upside optionality. The US generic business (550 approved ANDAs, 116 pending) remains a stable base despite pricing headwinds.
Analyst consensus projects a 3-year earnings CAGR of ~12%, with revenue CAGR of ~10%. The reduction in US-India reciprocal tariffs from 25% to 18% provides additional tailwind, improving FY27–FY28 earnings visibility for this US-exposed pharma name.
9. Risks & Catalysts
✅ Catalysts (Bull Factors)
⚠️ Risks (Bear Factors)
10. Peer Comparison
| Company | Mkt Cap (₹ Cr) | Revenue (₹ Cr) | P/E (TTM) | EBITDA Margin | Revenue CAGR (5Y) | Rating |
|---|---|---|---|---|---|---|
| Sun Pharma ★ | 4,31,000 | 52,578 | 38.3× | 30.9% | ~10% | BUY |
| Dr. Reddy’s Labs | ~88,000 | ~30,000 | 19.0× | ~26% | ~13% | HOLD |
| Cipla | ~1,05,000 | ~26,000 | 26.5× | ~24% | ~9% | HOLD |
| Divi’s Laboratories | ~1,30,000 | ~9,200 | 68.0× | ~32% | ~8% | HOLD |
| Lupin | ~75,000 | ~21,000 | 30.0× | ~20% | ~10% | ACCUMULATE |
| Sector Median | — | — | ~28× | ~25% | ~10% | — |
Sun Pharma commands a deserved premium to peers given its superior margins, scale, specialty portfolio, and global reach. At 38× P/E vs sector median of ~28×, the premium (~35%) is partially justified but leaves limited room for error. Dr. Reddy’s trades at a discount (19× P/E) with faster revenue growth — a viable alternative for value-oriented investors. Divi’s appears most expensive on P/E but operates in a different (CDMO/API) segment.
Investment Verdict
Sun Pharmaceutical is India’s premier pharmaceutical franchise — a rare combination of scale, margin quality, and an evolving specialty narrative. The Q3 FY26 results were unambiguously strong: revenue grew 15%, EBITDA margin hit 30.9%, and net profit grew 16% YoY, beating estimates by a wide margin. The upcoming GLP-1 launches (Noveltreat, Sematrinity) and the global Ilumya ramp provide meaningful growth catalysts over FY27–FY28.
At the current CMP of ₹1,769, the stock trades at an ~8% discount to our DCF intrinsic value of ₹1,920 and at a 38× P/E — not cheap, but justified given the quality of the franchise. The base-case 12-month price target is ₹2,050, implying a 15.9% upside from current levels. Analyst consensus (38 analysts) supports a Buy with an average target of ₹1,949–₹1,981.
We recommend accumulating in the ₹1,650–₹1,800 zone with a 2–3 year horizon. Key risks to watch: US FDA actions, Novo Nordisk semaglutide litigation, and specialty pipeline execution.
